ABIOMED Financial Statements (ABMD)
|
|
|
|
Report date
|
|
|
03.02.2022 |
31.03.2022 |
20.05.2022 |
04.08.2022 |
03.11.2022 |
|
03.11.2022 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
261.2 |
269.9 |
269.9 |
277.1 |
265.9 |
|
1 083 |
|
Operating Income, bln rub |
|
|
64.6 |
65.0 |
65.0 |
66.1 |
58.0 |
|
254.1 |
|
EBITDA, bln rub |
? |
|
71.6 |
74.8 |
75.2 |
72.7 |
64.7 |
|
287.4 |
|
Net profit, bln rub |
? |
|
45.8 |
60.3 |
60.3 |
54.6 |
106.1 |
|
281.3 |
|
|
OCF, bln rub |
? |
|
90.5 |
|
79.0 |
68.1 |
13.4 |
|
160.5 |
|
CAPEX, bln rub |
? |
|
6.48 |
|
14.9 |
6.78 |
5.61 |
|
27.3 |
|
FCF, bln rub |
? |
|
84.0 |
|
64.1 |
61.3 |
7.81 |
|
133.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
|
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
148.5 |
153.4 |
153.4 |
158.5 |
159.0 |
|
624.3 |
|
Cost of production, bln rub |
|
|
47.6 |
51.5 |
51.5 |
52.6 |
48.9 |
|
204.4 |
|
R&D, bln rub |
|
|
40.9 |
43.8 |
43.8 |
40.5 |
42.1 |
|
170.1 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
9.76 |
3.77 |
80.7 |
|
94.2 |
|
|
Assets, bln rub |
|
|
1 593 |
1 673 |
1 673 |
1 704 |
1 697 |
|
1 697 |
|
Net Assets, bln rub |
? |
|
1 433 |
1 503 |
1 503 |
1 536 |
1 540 |
|
1 540 |
|
Debt, bln rub |
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
Cash, bln rub |
|
|
669.2 |
758.6 |
758.6 |
844.3 |
820.4 |
|
820.4 |
|
Net debt, bln rub |
|
|
-669.2 |
-758.6 |
-758.6 |
-844.3 |
-820.4 |
|
-820.4 |
|
|
Ordinary share price, rub |
|
|
359.2 |
331.2 |
331.2 |
247.5 |
245.7 |
|
377.5 |
|
Number of ordinary shares, mln |
|
|
45.5 |
45.5 |
45.5 |
45.6 |
45.4 |
|
45.4 |
|
|
Market cap, bln rub |
|
|
16 345 |
15 074 |
15 079 |
11 280 |
11 146 |
|
17 126 |
|
EV, bln rub |
? |
|
15 676 |
14 315 |
14 321 |
10 436 |
10 326 |
|
16 306 |
|
Book value, bln rub |
|
|
1 309 |
1 387 |
1 381 |
1 413 |
1 417 |
|
1 417 |
|
|
EPS, rub |
? |
|
1.01 |
1.33 |
1.33 |
1.20 |
2.34 |
|
6.20 |
|
FCF/share, rub |
|
|
1.85 |
0.00 |
1.41 |
1.35 |
0.17 |
|
2.94 |
|
BV/share, rub |
|
|
28.8 |
30.5 |
30.3 |
31.0 |
31.2 |
|
31.2 |
|
|
EBITDA margin, % |
? |
|
27.4% |
27.7% |
27.9% |
26.2% |
24.3% |
|
26.5% |
|
Net margin, % |
? |
|
17.5% |
22.4% |
22.4% |
19.7% |
39.9% |
|
26.0% |
|
FCF yield, % |
? |
|
1.14% |
0.91% |
1.34% |
1.86% |
1.95% |
|
0.78% |
|
ROE, % |
? |
|
8.51% |
13.9% |
13.9% |
13.4% |
20.3% |
|
18.3% |
|
ROA, % |
? |
|
7.65% |
12.5% |
12.5% |
12.1% |
18.4% |
|
16.6% |
|
|
P/E |
? |
|
134.1 |
72.2 |
72.2 |
54.7 |
35.7 |
|
60.9 |
|
P/FCF |
|
|
88.1 |
|
74.9 |
53.9 |
51.3 |
|
128.6 |
|
P/S |
? |
|
16.0 |
14.5 |
14.5 |
10.5 |
8.35 |
|
15.8 |
|
P/BV |
? |
|
12.5 |
10.9 |
10.9 |
7.98 |
7.87 |
|
12.1 |
|
EV/EBITDA |
? |
|
78.2 |
51.4 |
51.5 |
36.7 |
29.6 |
|
56.7 |
|
Debt/EBITDA |
|
|
-3.34 |
-2.72 |
-2.73 |
-2.97 |
-2.35 |
|
-2.85 |
|
|
R&D/CAPEX, % |
|
|
630.9% |
|
294.0% |
596.7% |
750.4% |
|
623.6% |
|
|
CAPEX/Revenue, % |
|
|
2.48% |
0.00% |
5.52% |
2.45% |
2.11% |
|
2.52% |
|
| ABIOMED shareholders |
